title: Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
authors.affiliation: Dept of Family Medicine, University of Washington, Seattle, USA. nichart@u.washington.edu
authors.forename: N M
authors.initials: NM
authors.lastname: Hartnett
authors.forename: B G
authors.initials: BG
authors.lastname: Saver
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D003408:Cresols / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D010665:Phenylpropanolamine; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D000068737:Tolterodine Tartrate; D001745:Urinary Bladder Diseases / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy*
chemical_list: D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D003408:Cresols; D003692:Delayed-Action Preparations; D008333:Mandelic Acids; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin